Stoke Therapeutics, Inc. (NASDAQ:STOK) Stock Has Average Target Price of $44.17

Shares of Stoke Therapeutics, Inc. (NASDAQ:STOK) have received an average recommendation of “Moderate Buy” from the eleven analysts that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating and ten have issued a buy rating on the company. The average 12-month price objective among brokers that have issued ratings on the stock in the last year is $44.17.

STOK has been the subject of a number of research reports. Weiss Ratings lowered shares of Stoke Therapeutics from a “sell (d)” rating to a “sell (d-)” rating in a report on Wednesday, November 4th. Canaccord Genuity Group decreased their price target on shares of Stoke Therapeutics from $60.00 to $58.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Guggenheim reaffirmed a “buy” rating and set a $60.00 price target on shares of Stoke Therapeutics in a research note on Tuesday, August 4th. The Goldman Sachs Group reaffirmed a “buy” rating and set a $43.00 price target on shares of Stoke Therapeutics in a research note on Friday, October 30th. Finally, Chardan Capital reiterated a “buy” rating and set a $35.00 price target on shares of Stoke Therapeutics in a report on Tuesday, August 4th.

Stoke Therapeutics Trading Up 1.8%

STOK traded up $0.48 on Thursday, reaching $26.68. The stock had a trading volume of 420,156 shares, compared to its average volume of 1,384,656. The company has a market capitalization of $1.75 billion, a price-to-earnings ratio of -7.08 and a beta of 1.36. Stoke Therapeutics has a fifty-two week low of $22.05 and a fifty-two week high of $40.22. The firm has a 50-day moving average of $26.45 and a 200-day moving average of $30.75.

Stoke Therapeutics (NASDAQ:STOK) last announced its quarterly earnings results on Thursday, October 29th. The company reported ($1.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.15). Stoke Therapeutics had a negative net margin of 862.07% and a negative return on equity of 67.30%. The firm had revenue of $11.26 million for the quarter, compared to analyst estimates of $8.21 million. Sell-side analysts anticipate that Stoke Therapeutics will post -3.91 EPS for the current fiscal year.

Insider Activity at Stoke Therapeutics

In related news, insider Barry Ticho sold 1,051 shares of the firm’s stock in a transaction on Thursday, October 1st. The stock was sold at an average price of $26.16, for a total transaction of $27,494.16. Following the completion of the transaction, the insider directly owned 19,059 shares of the company’s stock, valued at $498,583.44. This trade represents a 5.23% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Edward Kaye sold 12,567 shares of Stoke Therapeutics stock in a transaction dated Tuesday, August 18th. The stock was sold at an average price of $32.03, for a total value of $402,521.01. Following the transaction, the director directly owned 124,557 shares in the company, valued at $3,989,560.71. The trade was a 9.16% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders sold 27,418 shares of company stock worth $860,914 over the last three months. Company insiders own 9.60% of the company’s stock.

Institutional Trading of Stoke Therapeutics

Institutional investors have recently added to or reduced their stakes in the stock. Quantbot Technologies LP bought a new position in Stoke Therapeutics during the 2nd quarter worth approximately $34,000. KBC Group NV acquired a new stake in Stoke Therapeutics during the first quarter worth approximately $36,000. Western Wealth Management LLC acquired a new stake in Stoke Therapeutics during the first quarter worth approximately $55,000. Sterling Capital Management LLC increased its holdings in Stoke Therapeutics by 849.7% in the third quarter. Sterling Capital Management LLC now owns 1,833 shares of the company’s stock worth $48,000 after purchasing an additional 1,640 shares in the last quarter. Finally, EverSource Wealth Advisors LLC increased its holdings in Stoke Therapeutics by 195.3% in the first quarter. EverSource Wealth Advisors LLC now owns 1,837 shares of the company’s stock worth $60,000 after purchasing an additional 1,215 shares in the last quarter.

Stoke Therapeutics Company Profile

Stoke Therapeutics, Inc. is a clinical-stage biotechnology company focused on developing genetic medicines for severe diseases caused by insufficient protein production. The company uses its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) platform to design antisense oligonucleotides that can increase the expression of specific genes and potentially address the underlying causes of genetic disorders. Stoke’s leading product candidate is STK-001, an investigational antisense oligonucleotide being developed for the treatment of Dravet syndrome, a severe genetic epilepsy most commonly associated with mutations in the SCN1A gene.